Sosei Seals Agreement With Biocopea

Sosei Group (Sosei) has entered into a deal with Biocopea Limited (Biocopea), a subsidiary of PepTcell, for the drug discovery program, SD281 and its analogues.

The company has said that SD281 and its analogues, based on a metabolite of a well-known drug, were shown to have pronounced anti-inflammatory properties. Sosei had positioned the compounds for intervention in inflammatory diseases such as Inflammatory Bowel Disease (IBD).

Reportedly, Biocopea plans to develop the portfolio of compounds further using its specialised chemical design, specific disease models and immunology expertise.

Under the terms of the assignment, Sosei will receive payments when the compounds are commercialised by Biocopea or its partners.

Sosei Group is an international biopharmaceutical company with expertise in product discovery and development.

Biocopea is focused on the identification and exploitation of novel biology from existing drug templates. It is 75% owned by PepTcell.